Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: FAP, Familial Adenomatous Polyposis
Interventions: R-1,3-Butanediol (10G-A), R-1,3-Butanediol (20G-A), R-1,3-Butanediol (30G-A), R-1,3-Butanediol (30G-B); Dietary Supplement
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: LY2439821, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Peoria, Arizona • La Mesa, California • Palm Desert, California + 34 more

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more

Conditions: Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: DS-3939a, Pembrolizumab, Carboplatin, Pemetrexed, DS-1103a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 4 more

Conditions: Small Cell Lung Cancer
Interventions: LBH589 and carboplatin with etoposide; Drug
Lead sponsor: Ahmad Tarhini; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Stroke
Interventions: Haloperidol, Typical Antipsychotics, Atypical Antipsychotics; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,234,412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Addiction
Interventions: Learning Session, Interest Circle Calls, Coaching, Website; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Not listed
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sacroiliitis, Sacroiliac Joint Pain
Interventions: sacroiliac joint injection; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Pain, Musculoskeletal Pain, Fibromyalgia, Virtual Reality
Interventions: Pain Rehabilitation Virtual Reality (PRVR), Standard Physiotherapy Rehabilitation (SPR); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Menlo Park, California • Palo Alto, California

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001, Pomalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 15
States / cities: Duarte, California • Irvine, California • San Francisco, California + 11 more

Conditions: Sarcoma
Interventions: doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis, quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more

Conditions: Lymphedema
Interventions: Ketoprofen, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
Interventions: Systemic therapy, StrataNGS; Other · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-small Cell Lung Cancer
Interventions: Blueberry powder; Dietary Supplement
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Lyme Borreliosis
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more

Conditions: Obesity & Overweight, Weight Management
Interventions: Culinary medicine classes, Medically Tailored Groceries, Shared Medical Appointments; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, Depression, Anxiety
Interventions: Computerized cognitive behavioral therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms
Interventions: E7386, Lenvatinib, Doxorubicin, Paclitaxel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 28
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 22 more

Conditions: Skin Appearance, Skin Texture, Skin Sagging, Wrinkles
Interventions: Multi-functional Home-use Beauty Device, Topical Skincare Serum, Skincare Mask; Device · Other
Lead sponsor: APR Co., Ltd.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Muscular Atrophy, Spinal
Interventions: Salanersen, Sham Procedure; Drug · Procedure
Lead sponsor: Biogen; Industry
Eligibility: 0 Days to 7 Months
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Flower Mound, Texas

Conditions: Overweight
Interventions: HU6; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostate Cancer
Interventions: EC1169, EC0652; Drug · Other
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more

Conditions: B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
Interventions: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19); Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 0 Years to 29 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: NNC0487-0111 A, NNC0487-0111 B, Placebo B (NNC0487-0111 B), Placebo A (NNC0487-0111 A); Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: San Antonio, Texas

Search by objective public record fields.

Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

A Study in Patients With Rheumatoid Arthritis

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

A Study of DS-3939a in Participants With Solid Tumors

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

Evaluating Improvement Strategies in Addiction Treatment

Imaging for SIJ Injection Therapy

Pain Rehabilitation Virtual Reality (PRVR): Innovations to Enhance Mobility in the Presence of Pain

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Lymphedema Study for Arm or Leg Lymphedema

PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Family-Based Weight Wellness Treatment Through Food is Medicine and Group Medical Visits in Pediatric and Adult Primary Care

Cognitive Behavioral Therapy and Real-time Self-management Intervention for SCD Via Mobile Applications

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Clinical Evaluation of a Multi-functional Beauty Device on Cosmetic Skin Outcomes

A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

Phase 1 of EC1169 In Patients With Recurrent MCRPC

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity